This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Stocks Testing The Coronavirus
by Daniel Laboe
If we can test the working population, we will be able to bring the healthy American's back to work and isolate those with the virus
Here's Why You Should Hold on to LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about LabCorp (LH) on its strong segmental results in the fourth quarter of 2019.
Bruker Inks Deal to Distribute Coronavirus Detection Test
by Zacks Equity Research
The agreement would make Bruker (BRKR) a key player in coronavirus diagnosis.
New Buyouts & Envigo Deal Aid LabCorp Amid Regulatory Woes
by Zacks Equity Research
LabCorp's (LH) Covance arm grows on strategic acquisitions including MI Bioresearch.
LabCorp Aims to Prioritize Inpatient Coronavirus Testing
by Debanjana Dey
LabCorp (LH) aims to serve the hospital inpatient population, with guidance provided by the CDC. It is also preparing to support faster point-of-care testing in hospitals.
Tech Giants Boost Efforts to Deal With Coronavirus Crisis
by Radhika Pujara
Here we discuss how tech giants including Microsoft (MSFT) and others are leaving no stone unturned to address COVID-19 crisis in innovative ways, backed by AI, ML and cloud computing capabilities.
Microsoft, Adaptive Biotech Collaborate to Fight COVID-19
by Zacks Equity Research
Microsoft (MSFT) extends partnership with Adaptive Biotechnologies on an open source dataset to aid the development of a diagnostic vaccine for COVID-19.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
4 Potential Gainers Amid Intensifying Coronavirus Fears
by Trina Mukherjee
Amid the pandemonium associated with coronavirus, we look into four stocks that have the potential to benefit from this outbreak.
QIAGEN Gets CE Nod for QIAstat-Dx Respiratory SARS-CoV-2 Test
by Zacks Equity Research
The regulatory clearance of this test has made QIAGEN (QGEN) a key player in coronavirus diagnosis.
Coronavirus Testing Players Gain Momentum: 3 Stocks in Focus
by Sriparna Ghosal
There are several key diagnostic testing laboratory and biotech players whose prospects seem bright on account of rigorous work on developing diagnostic testing for the coronavirus.
Thermo Fisher (TMO) Gets EUA From FDA for COVID-19 Testing
by Zacks Equity Research
The emergency authorization of this test has made Thermo Fisher (TMO) a key player in the field of coronavirus diagnosis.
Why Is LabCorp (LH) Down 22.5% Since Last Earnings Report?
by Zacks Equity Research
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BD MAX Gets CE Mark for Coronavirus Detection, Shares Up
by Zacks Equity Research
BD (BDX) and Spain's CerTest Biotec collaborate to detect the COVID-19 in Europe.
Quest Diagnostics (DGX) to Launch Coronavirus Test Service
by Zacks Equity Research
Quest Diagnostics (DGX) aims to mobilize effective public health response to the coronavirus outbreak through quality laboratory testing.
LabCorp (LH) Launches Test to Detect Presence of Coronavirus
by Zacks Equity Research
LabCorp (LH), with an aim to contain the outbreak of coronavirus, launches the LabCorp 2019 Novel Coronavirus (COVID-19), NAA test.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
by Sriparna Ghosal
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Bleak Outlook for Medical Dental Supplies Industry
by Sreyoshi Mukherjee
Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.
LabCorp's (LH) Q4 Earnings Beat Estimates, Margins Rise
by Zacks Equity Research
LabCorp (LH) registered year-over-year growth in operating segments in Q4.
Ares Management (ARES) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ares Management (ARES) delivered earnings and revenue surprises of 34.00% and 14.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More
by Urmimala Biswas
Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.
LabCorp (LH) Rides on Solid Diagnostics Despite PAMA Issues
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development delivers organic growth despite foreign currency headwind.
What's in the Offing for LabCorp's (LH) Earnings in Q4?
by Zacks Equity Research
With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.
LabCorp (LH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.